Quanterix (QTRX) Q1 2025 Earnings Call May 12, 2025 04:30 PM ET Company Participants Joshua Young - Head of Investor RelationsMasoud Toloue - CEOVandana Sriram - Chief Financial OfficerJake Allen - Healthcare Equity Research AssociatePuneet Souda - Senior MD Conference Call Participants Kyle Mikson - Managing Director & Senior Research AnalystSung Ji Nam - MD - Senior Healthcare AnalystDaniel Brennan - Senior Equity Research Analyst - Managing Director Operator Ladies and gentlemen, thank you for standing b ...

Stereotaxis (STXS) Q1 2025 Earnings Call May 12, 2025 04:30 PM ET Company Participants David Fischel - CEO & ChairmanKimberly Peery - CFOJoshua Jennings - Managing Director Conference Call Participants Adam Maeder - Managing Director & Senior Research AnalystFrank Takkinen - Senior Research AnalystJason Wittes - Managing Director & Senior Research Analyst Operator Good afternoon. Thank you for joining us for Stereotaxis First Quarter twenty twenty five Earnings Conference Call. Certain statements during the ...

Rapid7 (RPD) Q1 2025 Earnings Call May 12, 2025 04:30 PM ET Company Participants Elizabeth Chwalk - Head of Investor RelationsCorey Thomas - Chairman & CEOTim Adams - CFOSaket Kalia - Managing DirectorAaron Samuels - Equity Research AssociateMark Zhang - AVP - Equity ResearchGregg Moskowitz - Managing Director, Enterprise softwareGray Powell - Managing DirectorRoger Boyd - Executive DirectorJoshua Tilton - DirectorAidan Perry - Equity Research AssociateJoseph Gallo - Senior Vice PresidentAdam Borg - Managin ...

Xtant Medical (XTNT) Q1 2025 Earnings Call May 12, 2025 04:30 PM ET Company Participants Brett Maas - Managing PartnerSean Browne - President, CEO & DirectorScott Neils - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Senior Equity Research Analyst - HealthcareRyan Zimmerman - Managing Director & Medical Technology Analyst Operator Good afternoon, everyone, and welcome to the Xtant Medical First Quarter twenty twenty five Financial Results. Please note this conference is being re ...

OptimizeRx (OPRX) Q1 2025 Earnings Call May 12, 2025 04:30 PM ET Company Participants Steve Silvestro - CEOEdward Stelmakh - CFO & COORyan Daniels - Group Head–Healthcare Technology and ServicesAndrew D’silva - SVP - Corporate FinanceDavid Grossman - Managing DirectorMax Michaelis - Equity Research AssociateConstantine Davides - Managing DirectorJeff Garro - Managing Director Conference Call Participants Richard Baldry - MD & Senior Research Analyst Operator Good afternoon, everyone, and thank you for joini ...

Financial Data and Key Metrics Changes - For Q1 2025, revenues were $29.4 million, down from $38 million in Q1 2024, primarily due to lower development milestone revenues from the CSL collaboration as the COVID vaccine transitions to commercialization [19][20] - Research and development expenses decreased to $34.9 million from $53.6 million year-over-year, driven by lower manufacturing costs, with expectations for further declines in the second half of fiscal year 2025 [20][21] - General and administrative expenses were $11.3 million, down from $14.9 million in the same period last year, attributed to reduced share-based compensation costs [21] - The net loss for Q1 2025 was approximately $14.1 million, or $0.52 per diluted share, compared to a net loss of $3 million, or $1 per diluted share, in Q1 2024 [21] Business Line Data and Key Metrics Changes - The mRNA therapeutics pipeline is being prioritized, with significant focus on the CF and OTC programs, while the COVID vaccine program is transitioning to commercialization [11][18] - The ARCT032 program for cystic fibrosis is in Phase II, with enrollment expected to complete by the end of 2025, and interim data anticipated in mid-2025 [7][10] - The ARCT810 program for OTC deficiency is also in Phase II, with interim data expected in Q2 2025 [8][10] Market Data and Key Metrics Changes - The company received an initial milestone payment from CSL related to the EU approval of the COVID vaccine, with further payments anticipated as the program progresses [11][19] - The company is preparing for a Marketing Authorization Application in the UK in Q2 2025 and a BLA filing in the US in Q3 2025 [12] Company Strategy and Development Direction - The company has made a strategic decision to focus resources on mRNA therapeutics, particularly CF and OTC programs, due to current market conditions and regulatory uncertainties [18][19] - The STAR self-amplifying mRNA platform continues to receive positive feedback from publications, enhancing the company's position in the market [12][14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming clinical data from the CF and OTC programs, highlighting the potential for significant advancements in treatment options [22][23] - The company remains committed to maintaining a strong financial position, with a cash runway extended into 2028, allowing for the achievement of near-term milestones [21][22] Other Important Information - The company is utilizing a newly developed 15N ureogenesis assay to monitor the effects of ARCT810 in clinical development, which is expected to provide valuable data [10][18] - Long-term data from the COVID vaccine trial suggests a favorable safety profile, with no reports of myocarditis or pericarditis [14] Q&A Session Summary Question: Can you provide more details on the changes made to extend the cash runway and potential incoming cash flows? - Management indicated that tough decisions were made regarding cost reductions and focusing on critical programs, which contributed to extending the cash runway [27][28] Question: What milestones should we expect related to the UK and US approvals for the COVID vaccine? - There are no milestones associated with the UK or US approvals; however, a milestone is anticipated with the first US revenues from the COVID vaccine, expected in 2028 [30][31] Question: What is the expected size of the initial interim cohort for ARCT032 and the bar for success? - The interim data set is expected to include 6 to 9 subjects, with a bar for success set at a 3% improvement in lung function [35][36] Question: How does ARCT032 differ from competitor programs in terms of tolerability? - The company highlighted its exclusive LUNAR lipid nanoparticle delivery technology and the high purity of its mRNA constructs as key differentiators [42][43] Question: What are the expected biomarkers for the OTC program? - Management confirmed that glutamine, orotic acid, and other biomarkers will be measured to assess the effectiveness of the treatment [86][87]

Power Integrations (POWI) Q1 2025 Earnings Call May 12, 2025 04:30 PM ET Company Participants Joe Shiffler - Director of Investor Relations & Corporate CommunicationsBalu Balakrishnan - Chairman & CEOSandeep Nayyar - VP of Finance and CFORoss Seymore - Managing DirectorTore Svanberg - Managing Director Conference Call Participants David Williams - Equity Research AnalystChristopher Rolland - Senior Equity AnalystGus Richard - MD & Senior Research Analyst Operator Good afternoon, ladies and gentlemen, and we ...

Mineralys Therapeutics (MLYS) Q1 2025 Earnings Call May 12, 2025 04:30 PM ET Company Participants Dan Ferry - Managing DirectorJon Congleton - CEODavid Rodman - Chief Medical OfficerAdam Levy - CFOMichael Difiore - Managing DirectorSeamus Fernandez - Senior Managing DirectorAlice Nettleton - VP - US Pharmaceutical & Biotechnology Equity ResearchJayed Momin - Biopharma Equity Research AssociateSadia Rahman - Vice President, Biopharma Equity Research Conference Call Participants Richard Law - AnalystRami Katk ...

RCI Hospitality (RICK) Q2 2025 Earnings Call May 12, 2025 04:30 PM ET Company Participants Mark Moran - CEOEric Langan - Chairman, CEO & PresidentBradley Chhay - Chief Financial OfficerJason Scheurer - Founder & President Conference Call Participants None - Analyst Mark Moran Greetings, and welcome to RCI Hospitality Holdings second quarter twenty twenty five earnings conference call. You can find the company's presentation on RCI's website. Go to the Investor Relations section, and all the links are at the ...

Financial Data and Key Metrics Changes - For Q1 2025, the company reported revenues of $600,000, primarily driven by sales in the industrial verticals [23] - R&D and SG&A expenses for Q1 2025 were $14.1 million, including $1.9 million in non-cash charges related to stock-based compensation and $1.4 million in non-cash charges related to depreciation and amortization, resulting in a reduction of 45% year-over-year [24][25] - The company finished the quarter with $69 million in cash and cash equivalents, with additional availability under various facilities [26][27] Business Line Data and Key Metrics Changes - The automotive segment is engaged in seven RFQs, but progress has been slow due to OEMs focusing on supply chain issues and tariff impacts [7][19] - The industrial segment is seeing momentum, particularly in AGV and AMR applications, with expectations for commercial wins from ongoing evaluations [12][20] - The defense vertical is expanding, with a focus on partnerships and leveraging existing technology for military applications [14][22] Market Data and Key Metrics Changes - The automotive industry is navigating a complex landscape influenced by tariffs, leading to a focus on component costs and the origin of systems [19] - The industrial market is experiencing increased demand for automation and AI, with the company well-positioned to meet this demand [20][21] - The defense market presents multiple opportunities for technology application, including drones and unmanned vehicles, which differ significantly from automotive applications [106] Company Strategy and Development Direction - The company aims to strengthen its balance sheet and focus on custom development opportunities with OEMs in the automotive sector [11] - There is a strategic push towards the defense sector, with plans to engage with the Department of Defense and explore partnerships with larger companies [14][22] - The company is preparing for an Investor Day to showcase technology offerings and engage with potential customers [15] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the slow progress in automotive RFQs but remains optimistic about the long-term potential in this segment [11] - The company expects to generate $30 million to $50 million in revenue over the next 12 to 18 months, primarily from industrial engagements [28] - Management emphasizes the importance of patience and strategic engagement with customers to ensure sustainable growth [78] Other Important Information - The company has secured a production commitment with ZF in France, minimizing exposure to China tariffs and enhancing competitiveness [18] - The company plans to expand production capacity later in the year based on customer agreements [55] Q&A Session Summary Question: Is this the first quarter with commercial sales? - No, commercial sales were also present in Q4 [32] Question: What is driving the potential $30 million to $50 million revenue range? - Primarily driven by industrial automation and ADAS deployment [36][38] Question: How many unique entities is the company working with? - Less than 10 [45] Question: What is the scope of military opportunities? - The company is not a prime contractor but aims to be a technology partner for primes [46][47] Question: How does the company plan to compete with existing players in the industrial vertical? - By offering integrated solutions with software and achieving economies of scale [81][83] Question: What are the 2025 milestones to track? - Focus on signing commercial deals in industrial, engaging in pilot programs in defense, and developing partnerships in automotive [92][93]